Status and phase
Conditions
Treatments
About
This is a first-in-human open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-01473 given by intravenous infusion in participants with advanced solid cancers who have progressed or are intolerant of available standard therapies.
Full description
This study includes a dose escalation portion to determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) to evaluate the clinical activity of 23ME-01473 and further evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in participants with solid malignancies.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Females who are pregnant (positive serum pregnancy test within 7 days prior to study drug administration) or breastfeeding.
Immune-Related Medical History
Prior allogeneic or autologous bone marrow transplant, or other solid organ transplant
History of a positive test for:
Prior anticancer therapy, including chemotherapy, targeted therapy, biological therapy or immune-checkpoint inhibitors within 4 weeks or 5 drug half-lives (whichever is shorter)
History of another malignancy in the previous 2 years, unless cured by surgery alone and continuously disease free.
Uncontrolled or symptomatic CNS (central nervous system) metastases and/or carcinomatous meningitis
Recent history (within 6 months) of serious cardiovascular disease
Primary purpose
Allocation
Interventional model
Masking
82 participants in 1 patient group
Loading...
Central trial contact
Study Inquiry
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal